Xeris Biopharma Holdings, Inc. Stock Nasdaq
Equities
XERS
US98422L1070
Pharmaceuticals
Financials (USD)
Sales 2024 * | 184M | Sales 2025 * | 218M | Capitalization | 261M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -29M | EV / Sales 2024 * | 1.42 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.2 x |
P/E ratio 2024 * |
-4.47
x | P/E ratio 2025 * |
-7.79
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.58% |
Latest transcript on Xeris Biopharma Holdings, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Paul Edick
CEO | Chief Executive Officer | 67 | 21-04-30 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 21-09-30 |
John Shannon
PSD | President | 62 | 21-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |